---
schema_version: "secwatch.filing_event.v1"
accession: "0001326110-23-000121"
form_type: "8-K"
ticker: "IBRX"
cik: "0001326110"
company_name: "ImmunityBio, Inc."
filed_at: "2023-09-11T23:59:59+00:00"
generated_at: "2026-06-10T21:37:02.011115+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ImmunityBio restructures $470M in debt; gets $200M new capital from founder

## Summary
- Issued $200M convertible note to Nant Capital (founder affiliate) with 3-yr term, convertible at 50% premium to market price.
- Exchanged $270M of existing debt for 209,291,936 shares of common stock, deleveraging balance sheet.
- Extended $535M in debt maturities from Dec 2023 to Dec 2024.
- Net proceeds of ~$199M to fund regulatory, pre-commercialization for Anktiva (N-803) in bladder cancer.
- All transactions are related-party with Dr. Patrick Soon-Shiong, Executive Chairman and Global CSMO.

## SEC filing metadata
- accession: 0001326110-23-000121
- form_type: 8-K
- ticker: IBRX
- cik: 0001326110
- company_name: ImmunityBio, Inc.
- filed_at: 2023-09-11T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326110/000132611023000121/0001326110-23-000121-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326110/000132611023000121/ibrx-20230911.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326110-23-000121
- JSON: https://secwatch.observer/filing/0001326110-23-000121.json
- Plain text: https://secwatch.observer/filing/0001326110-23-000121.txt

## Key facts
- Material Agreements
  ImmunityBio, Inc. entered into Stock Purchase Agreement with Nant Capital, LLC, NantMobile, LLC, NantCancerStemCell, LLC valued at approximately $270 million in aggregate principal amount (effective 2023-09-11).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Nant Capital, LLC, NantMobile, LLC, NantCancerStemCell, LLC
  - Value: approximately $270 million in aggregate principal amount
  - Effective: 2023-09-11
  source text: Also on September 11, 2023, the Company, the Company’s wholly-owned subsidiary NantCell, Inc., Nant Capital, NantMobile, LLC (“NantMobile”) and NantCancerStemCell, LLC (“NCSC” and together with Nant Capital and NantMobile, the “Purchasers”), entered into a Stock Purchase Agreement (the “SPA”) pursuant to which the Purchasers exchanged certain existing convertible promissory notes, identified in the SPA as the “Notes,” representing approximately $270 million in aggregate principal amount and accrued and unpaid interest, in exchange for an aggregate of 209,291,936 shares of Common Stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326110/000132611023000121/0001326110-23-000121-index.htm
- Material Agreements
  ImmunityBio, Inc. entered into $200.0 million Convertible Promissory Note with Nant Capital, LLC valued at $200.0 million (effective 2023-09-11).
  - Action: entry
  - Agreement: notes offering
  - Counterparty: Nant Capital, LLC
  - Value: $200.0 million
  - Effective: 2023-09-11
  source text: On September 11, 2023, ImmunityBio, Inc. (the “Company”) executed a $200.0 million convertible promissory note with Nant Capital, LLC (“Nant Capital” or the “Investor”), an entity affiliated with Dr. Patrick Soon-Shiong, the Company’s Executive Chairman and Global Chief Scientific and Medical Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326110/000132611023000121/0001326110-23-000121-index.htm
- Material Agreements
  ImmunityBio, Inc. amended a notes offering with Nant Capital, LLC valued at approximately $535 million (effective 2023-09-11).
  - Action: amendment
  - Agreement: notes offering
  - Counterparty: Nant Capital, LLC
  - Value: approximately $535 million
  - Effective: 2023-09-11
  source text: Also on September 11, 2023, the Company and Nant Capital entered into a series of letter agreements pursuant to which the maturity dates of certain existing promissory notes with an aggregate principal amount of approximately $535 million entered into between the Company and Nant Capital were each extended from December 31, 2023 to December 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326110/000132611023000121/0001326110-23-000121-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.